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Summary
Protein cages, including viral capsids, ferritins, and
heat shock proteins (Hsps), can serve as nanocon-
tainers for biomedical applications. They are gene-
tically and chemically malleable platforms, with po-
tential as therapeutic and imaging agent delivery
systems. Here, both genetic and chemical strategies
were used to impart cell-specific targeting to the Hsp
cage from Methanococcus jannaschii. A tumor vascu-
lature targeting peptide was incorporated onto the ex-
terior surface of theHsp cage. This protein cage bound
to avb3 integrin-expressing cells. Cellular tropism was
also imparted by conjugating anti-CD4 antibodies to
the exterior of Hsp cages. These Ab-Hsp cage conju-
gates specifically bound to CD4+ cells. Protein cages
have the potential to simultaneously incorporate mul-
tiple functionalities, including cell-specific targeting,
imaging, and therapeutic agent delivery. We demon-
strate the simultaneous incorporation of two function-
alities, imaging and cell-specific targeting, onto the
Hsp protein cage.
Introduction
The fusion of nanotechnology and medicine has the po-
tential to transform diagnosis and therapeutics through
the development of nanometer-scale (5–100 nm) thera-
peutic and imaging agent delivery systems with cell-
specific tropisms. Incorporation of cell and tissue tar-
geting allows for the potential of enhanced imaging
capacity and precise therapeutic delivery. The objective
of this work was to demonstrate that a single protein
cage platform can simultaneously incorporate cell-
specific targeting and imaging agent delivery.
Spherical protein cage architectures can be viewed as
precisely assembled nanometer-scale containers. In na-
ture, viral capsids, ferritins, and some heat shock pro-
teins (Hsps) serve as examples of these architectures.
In these examples, the protein cage architecture self-
assembles from multiple copies of a limited number of
protein subunits. The assembled subunits present three
*Correspondence: myoung@montana.edu (M.J.Y.); tdouglas@
chemistry.montana.edu (T.D.)distinct surfaces for imparting function by design. These
are the exterior of the cage, the interface between sub-
units, and regions exposed on the interior cavity. The
subunits are highly amenable to both genetic and chem-
ical modification, and these surfaces can be modified
either individually or in combination without altering the
assembly and overall architecture of the cage. Atomic
resolution structural information identifies the precise
location of amino acids within protein cage architec-
tures. This detailed information enables the rational
design of genetic mutants with novel functional proper-
ties. We and others have demonstrated that protein
cages are robust platforms for chemical derivatization,
genetic manipulation, metal chelation, and encapsula-
tion [1–22]. Their multivalent nature allows for the in-
corporation of multiple functionalities within a single
nanoparticle. We are exploring the potential medical ap-
plications of protein cage architectures.
Other nano-scale therapeutic delivery systems also
being explored include: lipid micelles, silica nanopar-
ticles, polysaccharide colloids, pegylated liposomes,
polyamidoamine dendrimer clusters, and hydrogel dex-
tran nanoparticles [9, 23–46]. Additionally, antibody-me-
diated therapeutic delivery has proven successful in
both lab and clinical settings, and antibodies them-
selves may serve as therapeutic agents [47–64]. In this
work, we demonstrate that protein cage platforms are
an additional system to which medically relevant func-
tionalities can be incorporated.
The field of cell-specific targeting has been signifi-
cantly advanced by the in vivo use of phage display
techniques to identify targeting peptides [24, 25, 29,
36, 37, 65–68]. Small peptides have been identified
that target to the vasculature of a variety of tissues, or-
gans, and tumors [69–72]. Targeting peptides linked to
specific cargo molecules, such as therapeutic agents,
proapoptotic peptides, and quantum dots were able to
localize the cargo to the desired in vivo target [25, 29,
71, 73–76]. One characterized example is the targeting
peptide RGD-4C (CDCRGDCFC), which binds avb3 and
avb5 integrins that are prevalently expressed within tu-
mor vasculature [18, 25, 62, 77, 78]. Work by Arap
et al. demonstrated that RGD-4C-targeted doxorubicin
enhanced tumor regression at therapeutic concentra-
tions less than that required to demonstrate therapeutic
efficacy with nontargeted doxorubicin [25]. Subse-
quently, many researchers have utilized the RGD-4C
peptide motif for tumor targeting of liposomes, radiola-
bels, therapeutics, and adenoviral gene therapy vectors
[62, 75, 76, 79–92]. The effects of RGD-4C targeted ther-
apeutics are augmented due to the antiangiogenic prop-
erty of RGD-4C itself [25, 62, 76, 80, 91, 92]. Due to the
prior success of RGD-4C, it was chosen as a ‘‘proof of
concept’’ targeting peptide for genetic incorporation
into a small Hsp cage architecture.
In this study, we investigated the ability to introduce
cell targeting capacity to protein cage architectures.
Both peptides and antibodies were incorporated on
the exterior surface of Hsp cages and tested for their
ability to bind cell surface ligands. We also investigated
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cule on the Hsp cage interior along with targeting li-
gands on the exterior surface.
Results and Discussion
We have demonstrated that genetic addition of the
RGD-4C peptide or chemical conjugation of an anti-
CD4 monoclonal antibody (mAb) onto the exterior sur-
face of the small Hsp cage architecture confers specific
cell targeting capacity. In addition, we were able to load
a cargo molecule, a fluorescent imaging agent (fluores-
cein), within the interior cavity of the Hsp cage. These re-
sults demonstrate the multifunctional capacity of pro-
tein cage architectures and their potential utility in
medicine.
For these studies, we chose to use a small Hsp cage,
which we previously established as a robust platform for
genetic and chemical manipulation [4, 5]. The small Hsp
cage from the hyperthermophilic archaeon, Methano-
coccus jannaschii, assembles from 24 identical subunits
into a 12 nm diameter empty sphere [93]. In order to im-
part avb3 and avb5 integrin targeting capabilities to the
Hsp cage, the RGD-4C peptide was genetically incorpo-
rated into a previously described Hsp variant (HspG41C)
[4, 5]. Both of these integrins are prevalently expressed
on angiogenic tumor vasculature [25, 62]. The HspG41C
mutant presents unique reactive cysteine residues on
the interior surface of the assembled cage for attach-
ment of cargo molecules. Protein modeling, based on
crystallographic data, indicates that C-terminal amino
acid residues 140–146 are found on the exterior surface
of the Hsp cage [93, 94]. An Hsp C-terminal RGD-4C fu-
sion protein was genetically engineered to present ex-
posed RGD-4C loops on the exterior of the protein
cage. Glycine residues (SGGCDCRGDCFCG) were
added both before and after the RGD-4C insert to ex-
tend the peptide away from the C terminus and allow
for some structural flexibility. The insert was confirmed
by DNA sequencing, and the new tumor-targeting Hsp
cages were expressed and purified from an Escherichia
coli expression system. Mass spectrometry verified
the average subunit mass of HspG41C-RGD4C to be
17,814.3 compared to the predicted mass of 17,814.6
(see the Supplemental Data, available with this article
online). The HspG41C-RGD4C mutant assembled as well
as the wild-type protein cage (Figure 1). HspG41C-
RGD4C protein cage purification did not require reduc-
ing agents to prevent intercage aggregation, suggesting
that the four cysteines present in each RGD-4C loop are
disulfide bonded.
Characterization of recombinant HspG41C-RGD4C
protein cages by size exclusion chromatography, dy-
namic light scattering (DLS), and transmission electron
microscopy (TEM) demonstrated that the overall spher-
ical structure of the Hsp cage was not compromised
due to the incorporation of the RGD-4C peptide (Fig-
ure 1). Size exclusion chromatography elution profiles
of HspG41C-RGD4C cages indicate that the cages are
slightly larger than the HspG41C parent cage lacking
the targeting peptide (Figure 1) [5]. This observation
was supported by DLS, which indicated a larger average
diameter for the HspG41C-RGD4C cages (15.46 0.3 nm
[mean 6 SD]) as compared to HspG41C (12.7 6 0.5 nm)(Figure 1). TEM images of the HspG41C-RGD4C cages
and HspG41C cages are indistinguishable (Figure 1) [5].
We chemically attached fluorescein molecules to
cysteine residues on Hsp cages in order to study cell-
specific targeting of HspG41C-RGD4C cages. This dem-
onstrates that both cell targeting and imaging function-
alities can be simultaneously incorporated into the Hsp
protein cage architecture. The HspG41C-RGD4C has a
total of 120 cysteines per cage (5 cysteines per subunit).
Substoichiometric labeling with fluorescein-5-maleimide
ensured that every cage displayed a significant fraction
of unmodified cysteines within the RGD-4C sequence.
The original RGD-4C peptides discovered by phage
display were in a cyclic conformation due to intrapeptide
disulfide bond formation [25, 29]. Likewise, we predicted
that RGD-4C peptides presented on HspG41C-RGD4C
architectures would also cyclize due to intrapeptide
disulfide bond formation. Hsp-fluorescein-conjugated
cages were purified from free fluorescein via size exclu-
sion chromatography, and the covalent nature of the
fluorescein-Hsp subunit linkage was demonstrated by
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Figure 1. Characterization of the avb3 Integrin-Targeted HspG41C-
RGD4C Protein Cage Architecture
(A) Size exclusion chromatography elution profile of HspG41C-
RGD4C cages (Abs 280 nm).
(B) Dynamic light scattering analysis of HspG41C-RGD4C (average
diameter 15.4 6 0.3 nm).
(C) Transmission electron micrograph (TEM) of the HspG41C-
RGD4C cages negatively stained with 2% uranyl acetate.
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163SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
(Figure 2; Supplemental Data). Absorbance spectros-
copy determined that, on average, there were 26 out
of the 120 possible cysteines per cage labeled with
fluoresceins; therefore, only a fraction of the cysteines
within the RGD-4C were bound to fluorescein. Qualita-
tive mass spectrometry analysis of fluorescein-labeled
HspG41C-RGD4C subunits indicated that there are
between one and five fluoresceins per subunit (Supple-
mental Data). Some of the RGD-4C peptides were pre-
sumably in ‘‘loop’’ conformation, whereas others were
potentially linearized depending on the number of conju-
gated fluorescein-5-maleimides per subunit [5]. Data
from mass spectrometry indicated the presence of
both the disulfide and the free thiol form of the RGD-
4C peptide. Previous structural studies of synthetic
RGD-4C peptides in solution revealed that there are
two predominant cyclic conformations, both of which
bind avb3 integrin, although one (RGD-A) exhibited
higher binding affinity [95]. However, in a second report,
synthetically produced acyclic RGD-4C was shown to
have higher binding affinity than the cyclic form [86].
Since the fluorescein-labeled HspG41C-RGD4C con-
structs most likely had a mixed presentation of ‘‘loop’’
and linearized RGD-4C targeting peptides, we hypothe-
sized that they would bind avb3 integrin-expressing
cells.
Figure 2. Characterization of Fluorescein-Labeled HspG41C-
RGD4C Cages
Size exclusion chromatography elution profile of HspG41C-RGD4C
cages. Coelution of the absorbance at 495 nm (fluorescein) and 280
nm (protein) illustrates that fluorescein is bound to intact Hsp ca-
ges. TEM micrograph (inset) also demonstrates the presence of
intact Hsp cages.Epifluorescence microscopy was used to visualize flu-
orescently labeled HspG41C-RGD4C cages bound to
avb3 integrin-expressing C32 melanoma cells in vitro
[96, 97]. For all microscopy studies, C32 melanoma cells
were grown on glass coverslips. Cell surface expres-
sion of avb3 integrin on C32 cells was verified by immu-
nofluorescence utilizing a fluorescein-conjugated anti-
avb3 mAb (LM609). HspG41C-RGD4C-fluorescein cages
were observed to efficiently bind C32 cells as compared
to control samples of Hsp cages without the RGD-4C
peptide (Figure 3). For direct comparison of epifluores-
cence data, the concentration of fluorescein was normal-
ized (2.5 mM), and the illumination intensity and the cam-
era exposure were held constant. HspG41C-RGD4C-
fluorescein protein cages were observed to efficiently
bind to C32 melanoma cells as compared to controls of
Hspprotein cages lacking the RGD-4C peptide (Figure 3).
In order to ensure that HspG41C-RGD4C-fluorescein
interaction with C32 cells was not mediated solely by ex-
terior RGD-4C bound fluorescein, an additional mutant
with surface-exposed cysteine residues (HspS121C)
was also tested. The HspS121C-fluorescein cages bind
fluorescein-5-maleimide via externally facing cysteines,
but lack the RGD-4C targeting sequences. These control
cages did not bind C32 cells at a level detectable by epi-
fluorescence microscopy, indicating the cell binding ob-
served for HspG41C-RGD4C was due to the presence of
the RGD-4C peptide (Figure 3).
Fluorescence-activated cell sorting (FACS) was used
to quantify the ability of fluorescein-labeled HspG41C-
RGD4C cages to bind C32 melanoma cells. Adherent
C32 melanoma cells were nonenzymatically disassoci-
ated from cell culture dishes and suspended in DPBS
plus Ca2+/Mg2+. Fluorescently labeled Hsp cage prepa-
rations were incubated with cells on ice at a normalized
fluorescein concentration of 2 mM and cells were washed
prior to FACS. C32 melanoma cell-associated fluo-
rescence was dramatically increased after incubation
with HspG41C-RGD4C-fluorescein cages. The geomet-
ric mean (geo. mean) fluorescence intensity value of
1410 clearly indicated that targeted HspG41C-RGD4C
cages exhibited cell binding in vitro (Figure 4A). C32 mel-
anoma cells do exhibit a background level of autofluor-
escence with geo. mean fluorescence intensity value of
66 (Figure 4A). A positive control experiment, in which
C32 melanoma cells were incubated with a fluorescein-
conjugated anti-avb3 mAb, also showed the expectedFigure 3. Epifluorescence Microscopy of
C32 Melanoma Cells with Hsp Cage Fluores-
cein Conjugates
Cells were incubated with (A) nontargeted
HspG41C-Fl cages with interiorly bound
fluorescein, (B) avb3 integrin targeted
HspG41CRGD4C-Fl cages and (C) nontar-
geted HspS121C-Fl cages with exteriorly
bound fluorescein. C32 melanoma cells
grown on coverslips were incubated with
Hsp cage fluorescein conjugates and im-
aged by both light (top) and fluorescent
microscopy (bottom). The fluorescein con-
centration for cage cell incubations was
2.5 mM, and all fluorescent images were
taken at a standardized camera exposure
time of 50 ms. Scale bar, 50 mm.
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164Figure 4. SpecificBindingofHspG41CRGD4C-
Fluorescein-Labeled Cages to C32 Melanoma
Cells
The FACS data of C32 cells incubated with
Hsp-fluorescein cages are plotted as his-
tograms labeled with their corresponding
geometric (geo.) mean fluorescence inten-
sity values. The background level of C32
cell-associated fluorescence (blue solid line;
geo. mean = 66) and the increased level of
C32 cell-associated fluorescence due to
binding of HspG41CRGD4C-Fl cages (green
filled plot; geo. mean = 1410) are shown.
(A) Nontargeted cages HspG41C-fluorescein
labeled interiorly (red dashed line; geo.
mean = 129).
(B) Nontargeted HspS121C-Fl cages with ex-
teriorly bound fluorescein (orange dotted
line; geo. mean = 216).
(C) Anti-avb3 integrin mAb blocked C32 mel-
anoma cells subsequently incubated with
HspG41CRGD4C-Fl cages (dashed purple
line; geo. mean = 353).
(D) mAb concentration-dependent blocking
of avb3 integrin on C32 cells demonstrated
by subsequent incubation of blocked cells
with HspG41CRGD4C-Fl (2.4 mM subunit in
the assembled cage, corresponding to
0.1 mM cage); 1.3 mM mAb (purple solid line;
geo. mean = 353), cells blocked with 0.65 mM
(green solid line; geo. mean = 714), 0.065 mM
mAb (solid black line; geo. mean = 1235).increase in fluorescence (geo. mean, 1037) associated
with cell-specific binding of the antibody (Supplemental
Data). FACS analysis of nontargeted cages (HspG41C-
fluorescein inside; HspS121C-fluorescein outside) indi-
cated low levels of nonspecific binding of protein cages
and fluorescein to C32 melanoma cells (geo. mean in-
tensities of 129 and 216, respectively, Figures 4A–4B).
In all cases, these results were independent of incuba-
tion time, which ranged from 20 min to 2 hr (data notshown). The binding specificity of RGD-4C-targeted
Hsp cages was tested with competition experiments.
For these studies, C32 melanoma cells were preincu-
bated with either unlabeled anti-avb3 mAb or unlabeled
HspG41C-RGD4C prior to incubation with fluorescently
labeled HspG41C-RGD4C cages. FACS analysis dem-
onstrated a reduction of RGD-4C-targeted cage binding
(Figures 4 and 5). As stated above, for FACS analysis,
the fluorescein concentration was normalized (2 mM);Figure 5. HspG41CRGD4C-Fluorescein Cage Interaction with C32 Melanoma Cells is Blocked by Unlabeled HspG41C-RGD4C but Not by
HspG41C or Albumin
FACS data from C32 melanoma cells incubated with an unlabeled blocking protein (HspG41C-RGD4C, HspG41C, or bovine albumin) prior to
incubation with HspG41CRGD4C-fluorescein cages are plotted as histograms labeled with their corresponding geo. mean fluorescence inten-
sity values. The background level of C32 cell-associated fluorescence (blue solid line; geo. means = 87 and 95) and the increased level of C32
cell-associated fluorescence due to binding of HspG41CRGD4C-Fl cages (50 mg/ml) (green filled plots; geo. mean = 1140 and 1685), in the
absence of any blocking protein, are shown.
(A) Unlabeled HspG41C-RGD4C concentration-dependent blocking; 5000 mg/ml (light purple solid line; geo. mean = 501), 500 mg/ml (dark pur-
ple dashed line; geo. mean = 748), cells blocked with 50 mg/ml (solid black line; geo. mean = 905).
(B) Unlabeled HspG41C does not block HspG41CRGD4C-Fl cage interaction with C32 cells; 5000 mg/ml (light purple solid line; geo. mean =
1546), 500 mg/ml (dark purple dotted line; geo. mean = 1813), cells blocked with 50 mg/ml (solid black line; geo. mean = 1830).
(C) Unlabeled bovine albumin (5000 mg/ml) does not block HspG41CRGD4C-Fl cage interaction with C32 cells (light purple solid line; geo.
mean = 1469).
Note: All FACS machine settings were identical, but data set (A) was collected on a different day than sets (B) and (C).
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165Figure 6. Specific Binding of Anti-CD4 mAb-
Conjugated HspG41C-Fluorescein Cages to
CD4+ Lymphocytes
FACS analysis of murine splenocytes incu-
bated with: (A) anti-CD4 mAb HspG41C fluo-
rescein cage conjugates (Ab-Hsp-Fl) bound
21% of cells within this population; (B) anti-
CD4 mAb-fluorescein demonstrated that
19% of this splenocyte population is CD4+;
(C) CD4+ cells blocked with unlabeled anti-
CD4 mAb, then subsequently exposed to
Ab-Hsp-Fl cage conjugates, demonstrated
a low level of nonspecific binding (2%); cor-
responding to (D) nontargeted HspG41C-
fluorescein cages (2%).this amount of fluorescein corresponds to 50 mg/ml (2.4
mM) HspG41C-RGD4C subunit in the assembled cage
(corresponding to 0.1 mM cage); the ratio of fluorescein
per subunit is near one to one. The degree of both anti-
body and HspG41C-RGD4C blocking was concentra-
tion-dependent. In order to compare the effectiveness
of different blocking proteins, we compared them on
a molar basis. At anti-avb3 integrin mAb concentrations
of 0.065 mM (10 mg/ml), minimal inhibition was observed.
At 0.65 mM (100 mg/ml) some inhibition was evident, and
finally, at 1.3 mM (200 mg/ml), binding was inhibited to
levels corresponding to that of nontargeted cages
(Figure 4D). Likewise, unlabeled HspG41C-RGD4C re-
duces the binding of HspG41CRGD4C-Fl in a concentra-
tion-dependent manner (Figure 5). Blocking of the RGD-
4C-avb3 integrin interaction was demonstrated to be
specific, since equivalent amounts of either HspG41C
or bovine albumin (fraction V) did not decrease the bind-
ing of HspG41CRGD4C-Fl to C32 melanoma cells (Fig-
ure 5). Together, these data illustrate the effective ge-
netic introduction of avb3 integrin targeting capacity to
the Hsp cage architecture.
The versatility of protein architectures for cell-specific
targeting was demonstrated by the chemical introduc-
tion of lymphocyte targeting to Hsp architectures. An
anti-CD4 mAb (GK1.5; American Type Culture Collection
[ATCC], Manassas, VA) was conjugated to fluorescein-
labeled HspG41C cages via the heterobifunctional cross-
linker sulfo-SMCC (sulfosuccinimidyl 4-[N-maleim-
idomethyl] cyclohexane-1-carboxylate). Size exclusion
chromatography was utilized to purify anti-CD4-
HspG41C-fluorescein cage conjugates (Ab-Hsp-Fl) from
HspG41C-fluorescein cages. The elution profile indi-
cated that the Ab-Hsp-Fl cage conjugates were larger
than HspG41C-Fl cages, and DLS confirmed the size
increase from 12.2 nm to 226 0.1 nm diameter (Supple-
mental Data).
FACS and epifluorescence microscopy were used to
investigate binding of anti-CD4-HspG41C-fluorescein(Ab-Hsp-Fl) cages to CD4+ cells within a murine spleno-
cyte population. A comparison of epifluorescence mi-
croscope images in which Ab-Hsp-Fl, Hsp-Fl, or Ab-Fl
were each combined individually with murine spleno-
cytes illustrated that Ab-Hsp-Fl bound to a similar num-
ber of cells as the Ab-Fl-positive control (Supplemental
Data). FACS was used for quantitative analysis of this in-
teraction. Ab-Hsp-Fl cages specifically bound to 21% of
the total cells within this population (Figure 6A). This
level of binding is consistent with the percentage of
CD4+ cells within this murine splenocyte population as
determined by binding of a fluorescein conjugated anti-
CD4 mAb to 19% of this murine splenocyte population
(Figure 6B). Further confirmation of binding specificity
was obtained from antibody blocking experiments.
Splenocytes were incubated with unlabeled anti-CD4
mAb, washed to remove unbound blocking antibody,
and subsequently incubated with Ab-Hsp-Fl cage con-
jugates. FACS analysis of this blocking experiment dem-
onstrated that only 2% of the population exhibited cell-
associated fluorescence (Figure 6C). This percentage of
cell fluorescence corresponds to that observed with
nontargeted HspG41C-fluorescein cages (2%) (Fig-
ure 6D). The observed binding of Ab-Hsp-Fl cages to
21% of the murine splenocyte population encompasses
both the specific binding to CD4+ lymphocytes (19%) on
top of a small, nonspecific level of background associa-
tion (2%). This indicates that immuno-targeted protein
cages effectively target to specific cells within a mixed
population.
In this work, the 12 nm diameter Hsp cage was both
genetically and chemically modified to incorporate
cell-specific targeting properties. Genetic incorporation
of avb3 integrin binding RGD-4C peptide onto the exte-
rior surface of Hsp cages conferred cell-specific target-
ing capabilities to this protein cage architecture. It is
expected that many other cell targeting peptides, espe-
cially those discovered by in vivo phage display library
techniques, could also be incorporated into this and
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anti-CD4-antibody to Hsp cages, and subsequent tar-
geting of a subset of CD4+ cells within a population of
murinesplenocytes, demonstrated thesuccess andpos-
sibilities of immuno-targeted Hsp cages. Fluorescein, an
imaging agent, was covalently linked to protein cages,
demonstrating that these architectures can simulta-
neously incorporate multiple functionalities, including
cell-specific targeting and imaging agent delivery.
Significance
The overall significance of this research is that it ad-
vances the utility of protein cage nanocontainers as
platforms for combined cell-specific-targeted and im-
aging agent-targeted delivery systems. This opens ex-
citing avenues for the incorporation and cell-specific
delivery of other cargo molecules, such as magnetic
resonance (MR) imaging and therapeutic agents. We
demonstrate that the Hsp cage architecture can be ge-
netically and chemically modified to impart mamma-
lian cell targeting capacity. This work also demon-
strates the ability to simultaneously incorporate cell
targeting and imaging agents within a single protein
cage. Protein cage architectures are precisely defined
monodisperse molecular platforms with inherent ge-
netic and chemical versatility. A library of protein
cage architectures is available, ranging in size from 9
to > 100 nm diameter, extending the utility of this ap-
proach to diverse applications.
Experimental Procedures
Genetic Engineering of avb3 Integrin Targeting
HspG41C-RGD4C
Methanococcus jannaschii genomic DNA was obtained from ATCC
(43607). As described previously, the gene encoding the small Hsp
(Mj HSP16.5) was polymerase chain reaction (PCR)-amplified and
cloned into NdeI/BamHI restriction sites of the PET-30a(+) vector
(Novagen, Madison, WI) for expression of the full-length protein
with no additional amino acids. PCR-mediated site-directed muta-
genesis was employed to replace the glycine at position 41 with
a unique cysteine residue, therefore generating the HspG41C mu-
tant [5]. Deletion of the HSP-stop codon directly upstream of the
BamHI site was also accomplished by PCR-mediated site-directed
mutagenesis. This deletion allowed for the insertion of additional se-
quence into the BamHI site to create the RGD-4C (CDCRGDCFC)
carboxyl-terminal fusion protein engineered to present exposed
RGD-4C loops on the exterior of the protein cage. The HspG41C-
RGD4C fusion protein was engineered to have extra glycine resi-
dues (italicized below), both before and after the RGD-4C insert, to
extend the insert away from the C terminus and allow some struc-
tural flexibility. Complimentary RGD-4C encoding primers with
gatc overhangs for cloning into the BamHI site (+sense primer: 50
ga tct gga gga tgc gac tgc cgc gga gac tgc ttc tgc gga taa gga 30;
encoding S GG C D C RGDC F CG stop) were mixed at a 1:1 molar
ratio, annealed, and treated with kinase (Promega, Madison, WI).
These inserts were subsequently ligated into an alkaline phospha-
tased, BamHI digested vector overnight at 17ºC and transformed
into XL-2 ultracompetant E. coli (Stratagene, La Jolla, CA). Trans-
formants were screened for the presence of the RGD-4C insert
and confirmed by sequencing the PCR amplified product on an
ABI 310 automated capillary sequencer with BigDye Chain termina-
tion sequence technology (Applied Biosystems, Foster City, CA).
HspG41C-RGD4C Cage Purification and Characterization
All small Hsp cages (HspG41C, HspS121C, and HspG41C-RGD4C)
were purified from an E. coli heterologous expression system as pre-
viously described [5]. One liter cultures of E. coli (BL21 [DE3] Bstrain) containing pET-30a(+) MjHsp16.5 plasmid were grown over-
night in LB plus kanamycin medium (37ºC, 220 rpm). Cells were har-
vested by centrifugation at 37003 g for 15 min (Heraeus 3334 rotor,
Sorvall Centrifuge) and resuspended in 30 ml of 100 mM HEPES, 50
mM NaCl, pH 8.0. Lysozyme, DNase, and RNase were added to final
concentrations of 50, 60, and 100 mg/ml, respectively. The sample
was incubated for 30 min at room temperature, French pressed
(American Laboratory Press Co., Silver Springs, MD), and sonicated
on ice (Branson Sonifier 250, power 4, duty cycle 50%, 33 5 min with
3 min intervals). Bacterial cell debris was removed via centrifugation
for 20 min at 12,000 3 g. The supernatant was heated for 15 min at
65ºC, thereby denaturing many E. coli proteins. The supernatant
was centrifuged for 20 min at 12,0003 g and purified by gel filtration
chromatography (Superose-6, Amersham-Pharmacia, Piscataway,
NJ; Bio-Rad Duoflow, Hercules, CA). Recombinant HspG41C-
RGD4C protein cages were routinely characterized by size exclusion
chromatography (Superose 6, Amersham Pharmacia), DLS (Broo-
khaven 90Plus, Brookhaven, NY), TEM (Leo 912 AB), SDS-PAGE,
and mass spectrometry (Acquity/Q-Tof micro; Waters, Milford,
MA). Protein concentration was determined by absorbance at 280
nm divided by the published extinction coefficient (9322 M21
cm21) [93].
Labeling Hsp with Activated Fluorescein Dye
Cysteine containing Hsp cages (100 mM HEPES, 50 mM NaCl, pH
6.5) were reacted with fluorescein-5-maleimide (Molecular Probes,
Eugene, OR) in concentrations ranging from 1–6 molar equivalents
per Hsp subunit for 30 min at room temperature, followed by over-
night incubation at 4ºC. Fluorescein-labeled Hsp cages were puri-
fied from free dye by size exclusion chromatography (DPBS pH
7.4). The number of fluorescein molecules per cage was calculated
from absorbance spectra [4, 5]. For example, HspG41C-RGD4C
(2 mg/ml; 112 mM subunit) reacted with 2.2 molar equivalents of
fluorescein-5-maleimide (246 mM) per Hsp subunit resulted in
HspG41C-RGD4C cages with an average of 26.2 fluoresceins per
cage (or 1.09 fluoresceins per subunit). The number of fluoresceins
per cage was quantified by absorbance spectroscopy [5].
C32 Amelanotic Melanoma Cell Culture
Human amelanotic melanoma cell line, C32, was obtained from
ATCC (CRL-1585). C32 cells were propagated in Minimum Essential
Medium Eagle (MEME) (ATCC 30–2003) supplemented with 10%
fetal bovine serum (Atlanta Biologicals, Norcross, GA), penicillin (100
U/ml), and streptomycin (100 mg/ml) (Sigma, St. Louis, MO) at 37ºC,
in a 5% CO2 incubator.
Mass Spectrometry
Hsp samples were analyzed by liquid chromatography/electrospray
mass spectrometry (LC/MS) (Acquity/Q-Tof micro; Waters).
HspG41C-RGD4C and derivatized HspG41C-RGD4C (5–15 ml, 0.3–
0.5 mg/ml) were injected onto a C8 column (208TP5115, Vydac)
and eluted with an H2O–acetonitrile linear gradient (eluent A:
0.1% formic acid in water; eluent B: 0.05% trifluoroacetic acid in
acetonitrile).
Epifluorescence Microscopy of C32 Melanoma Cells
Epifluorescence microscopy was performed on an Axioscope
2-Plus microscope (Zeiss) utilizing version 4.1 software and an Axio-
cam high-resolution camera (Hrc). For all microscopy studies, C32
melanoma cells were grown on glass coverslips to w60% conflu-
ency (MEME + 10% FBS), in the presence of penicillin (100 units/
ml) and streptomycin (100 mg/ml) (Sigma). C32 expression of the
RGD-4C target receptor, avb3 integrin, was verified by immunofluo-
rescence utilizing a fluorescein-conjugated anti-avb3 mAb (LM609)
(MAB1976F; Chemicon, Temecula, CA).
C32 cells grown on coverslips were incubated with Hsp cages in
serum-free medium for 30 min at 37ºC in a 5% CO2 incubator. The
fluorescein concentration of the Hsp-fluorescein preparations was
normalized to 2.5 mM to facilitate comparison. After incubation, the
cells were washed five times with Dulbecco’s phosphate-buffered
saline (DPBS; Sigma), fixed with 4% paraformaldehyde for 10 min,
washed with DPBS, and then mounted on slides in Vectashield
mounting medium (Burlingame, CA). Illumination intensity and cam-
era exposure times were held constant.
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Fluorescein-Conjugated Hsp Cages
Flow cytometry was performed on a FACSCalibur (Becton Dickin-
son, Mountain View, CA) and analyzed with Cell Quest software
(Becton Dickinson). Adherent C32 melanoma cells were nonenzy-
matically disassociated from cell culture dishes with DPBS without
Ca2+ or Mg2+ plus 1% ethylenediaminetetraacetic acid (EDTA;
w25 mM) (for about 2 min at room temperature), washed once
with serum-containing medium, and finally suspended in DPBS
plus Ca2+/Mg2+ at 2.1 3 106 cells/ml. Experiments were carried out
both in the presence and absence of 1% FBS in the buffer; results
were similar in both conditions. Fluorescently labeled cage prepara-
tions (normalized to 2 mM fluorescein) were incubated with cells on
ice from 20 min to 2 hr. After incubation, the cells were washed
five times with DPBS (both with and without Ca2+/Mg2+), and sus-
pended in DPBS plus 1% FBS for FACS analysis; 10,000 events
were counted for each condition. Both the anti-avb3 mAb (LM609)
(Chemicon MAB1976Z) and the corresponding fluorescein-conju-
gated anti-avb3 mAb (Chemicon MAB1976F) were used for FACS
analysis.
HspG41C-Fluorescein Anti-CD4 Antibody Conjugation
Fluorescein-labeled HspG41C protein cages were conjugated to
anti-CD4 monoclonal antibodies (generated from ATCC GK1.5) via
a heterobifunctional cross-linker, sulfosuccinimidyl 4-(N-maleimido-
methyl) cyclohexane-1-carboxylate (sulfo-SMCC; Pierce, Rockford,
IL). First, the antibodies (6.5 mg/ml in PBS, [pH 7.4]) were partially re-
duced with 10 mM tris(2-carboxyethyl)phosphine (TCEP) in the pres-
ence of 10 mM EDTA, with the final pH adjusted to 6.5, and incubated
for 2 hr at room temperature [98]. Simultaneously, the exposed ly-
sines (amines) of HspG41C-fluorescein cages (0.25 mg/ml; 15 mM
subunit in 500 ml DPBS, [pH 7.4]; 11 fluoresceins per cage) were re-
acted with the sulfo-NHS-ester component of the sulfo-SMCC linker
(added in excess 0.5 mg). The Hsp cage plus linker reaction was
incubated at room temperature for 1 hr, followed by the removal of
free sulfo-SMCC linker by size exclusion chromatography (desalting
column; Pierce). The reduced anti-CD4 antibodies were combined
with the HspG41C-fluorescein-SMCC cages and incubated for 3 hr
before final purification of anti-CD4-HspG41C-fluorescein cage
(Ab-Hsp) conjugates by size exclusion chromatography (Superose
6, Amersham-Pharmacia).
Murine Splenocyte Preparation
A BALB/c mouse spleen was homogenized in Hank’s balanced salt
solution (Mediatech, Herndon, VA) by pushing it through a 60 gauge
stainless-steel mesh; the homogenate was filtered through 100 mm
nylon mesh and centrifuged at 200 3 g for 10 min. The supernatant
was discarded and the cell pellet suspended in 5 ml ACK lysis buffer
(150 mM NH4Cl, 1 mM KHCO3, 0.1 mM Na2EDTA) for 5 min at room
temperature to lyse unwanted red blood cells. Lysis was stopped via
the addition of PBS plus 2% donor calf serum (25 ml). The remaining
white blood cells were pelleted by centrifugation at 200 3 g for 10
min and suspended in PBS plus 2% donor calf serum (2 3 107
cells/ml) containing anti-mouse Fc receptor antibody (from HB-
197, ATCC) in order to prevent nonspecific binding of antibodies
to the Fc receptor on lymphocytes. Cells were incubated on ice until
binding assays were performed.
Epifluorescence Microscopy of Splenocytes
Aliquots of murine splenocytes were combined with equal volumes
of each of the following: (A) anti-CD4-HspG41C-fluorescein (Ab-
Hsp-Fl) cages, (B) fluorescein-conjugated anti-CD4 mAb (positive
control), and (C) HspG41C-fluorescein cages (nontargeted control),
and incubated for 30 min on ice. Following incubation, the cells were
washed three times with PBS containing 2% donor calf serum. The
cells were wet-mounted prior to epifluorescence microscopy with
a Nikon Eclipse E800 microscope, equipped with a Nikon
DMX1200 digital camera utilizing MetaVue software. Illumination
intensity and camera exposure times were held constant.
FACS Analysis of Splenocytes Incubated with Anti-CD4
mAb-Conjugated Hsp Cages
FACS was performed on a FACSCalibur and analyzed with Cell
Quest software. Aliquots of murine splenocytes were combinedwith equal volumes of each of the following: (A) anti-CD4-
HspG41C-fluorescein (Ab-Hsp-Fl) cages, (B) fluorescein conjugated
anti-CD4 mAb (positive control), and (C) HspG41C-fluorescein ca-
ges (nontargeted control), and incubated for 30 min on ice. Following
incubation, the cells were washed in PBS containing 2% donor calf
serum in preparation for FACS. FACS analysis was performed on
a gated murine splenocyte cell population. For anti-CD4 mAb block-
ing experiments, splenocytes were incubated for 30 min with unla-
beled anti-CD4 mAb and washed to remove unbound blocking anti-
body prior to incubation with Ab-Hsp-Fl cage conjugates.
Supplemental Data
Supplemental Data, including Figures S1–S6, are available at http://
www.chembiol.com/cgi/content/full/13/2/161/DC1/.
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